Comparison of ustekinumab, infliximab and combination therapy in moderately to severely active ulcerative colitis – a study protocol of a randomized, multicenter, head-to-head COMBO-UC trial

Comparison of ustekinumab, infliximab and combination therapy in moderately to severely active ulcerative colitis – a study protocol of a randomized, multicenter, head-to-head COMBO-UC trial

BackgroundUlcerative colitis (UC) is a chronic inflammatory bowel disease with a complex etiology that affects the large intestine. Characterized by chronic, bloody diarrhea, UC can lead to severe complications, including an increased risk of colorectal cancer. Despite advancements in conservative t...

Full description

Bibliographic Details
Main Authors: Renata Talar-Wojnarowska, Adam Fabisiak, Hubert Zatorski, Katarzyna Płoszka, Katarzyna Błaziak, Wojciech Fendler, Grażyna Rydzewska, Ewa Małecka-Wojciesko, Piotr Eder
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-09-01
Series:Frontiers in Medicine
Subjects:
inflammatory bowel diseases
ulcerative colitis
dual biological therapy
infliximab
ustekinumab
Online Access:https://www.frontiersin.org/articles/10.3389/fmed.2024.1458998/full

Internet

https://www.frontiersin.org/articles/10.3389/fmed.2024.1458998/full

Similar Items